WuXi Biologics Cayman has been granted a patent for a polypeptide complex that combines antibody variable regions with TCR constant regions. The complex can be used in treating diseases and disorders. The patent also covers methods of production, encoding polynucleotides, and compositions containing the complex. GlobalData’s report on WuXi Biologics Cayman gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights WuXi Biologics Cayman Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on WuXi Biologics Cayman, Personalized cancer vaccines was a key innovation area identified from patents. WuXi Biologics Cayman's grant share as of January 2024 was 18%. Grant share is based on the ratio of number of grants to total number of patents.

Bispecific polypeptide complex for treating diseases

Source: United States Patent and Trademark Office (USPTO). Credit: WuXi Biologics Cayman Inc

A recently granted patent (Publication Number: US11845796B2) discloses a polypeptide complex that includes a first polypeptide with a heavy chain variable domain of an antibody linked to a T cell receptor constant region, and a second polypeptide with a light chain variable domain of the same antibody linked to another T cell receptor constant region. The complex is designed to form a dimer with a stabilizing non-native interchain bond between the constant regions. The patent also describes the engineered CBeta and CAlpha components of the constant regions, along with specific sequences for conjunction domains and antigen-binding moieties. Notably, the polypeptide complex is distinct from bispecific complexes and involves engineered components for targeted antigen specificity.

Furthermore, the patent details various aspects of the polypeptide complex, including mutated cysteine residues in the engineered CBeta and CAlpha, absence of native glycosylation sites, retention or lack of specific loops in the engineered CBeta, and sequences for the engineered constant regions. The patent also covers conjugates, polynucleotides encoding the complex, host cells containing the polynucleotides, and a method for producing the polypeptide complex. By providing a comprehensive description of the structural and functional elements of the polypeptide complex, the patent aims to protect the innovative design and applications of this novel biopharmaceutical entity in targeted therapy.

To know more about GlobalData’s detailed insights on WuXi Biologics Cayman, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies